Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek email him directly: derekb.lowe@gmail.com
Twitter: Dereklowe
Eric Milgram over at PharmaConduct has an excellent post up on the same paper I've been discussing this morning. As another guy who's been around the block a few times in this industry, he's struck by many of the same points I am (to the point of also linking to Wikepedia's page on Poisson distributions!)
And he has some interesting data of his own to present, too - well worth checking out.
2. Jeffrey Soreff on December 12, 2009 9:47 PM writes...
I have a really dumb question. Has anyone tried looking for new drug leads by looking for binding at _all_ of the proteins coded for in the human genome, regardless of whether their function is known? With 23,000 genes, it seems like there should be the potential for a comparable number of useful drugs (ok, binding to structural proteins might not do anything useful...). Has anyone tried anything like that?
You would need binding assays for all of them. To justify the expense of doing so, you'd need a reason or two. Even with reasons, academia and biotech and big pharma all put together have a pretty lousy track record of turning molecules that bind particular proteins selectively into actual drugs -- or even tools that give unambiguous answers.
But the short answer to your question is "yes". It's called "systems biology" and "phenotypic screening".
5. Mutatis Mutandis on December 13, 2009 7:34 AM writes...
I don't think it makes much sense to target "all" of them, but I've heard people discuss the idea of identifying the central proteins and interactions in the signalling networks through systems biology, and then systematically discovering molecules to target all of those.
They would of course be useful tool compounds to explore systems biology further. But you could also put them on the shelf with the confidence that sooner or later nearly all these critical interactions will be found to be relevant to a pathology of some kind.
It seems unlikely that people will try to do this through binding assays, I would bet more on phenotypical studies (HCS and microarrays) aiming to find drugs that mimic phenotypes established by RNAi. However, I'd like that to be done on primary cells or at least stem-cell derived cells.
Having heard a couple of talks on the targets issue, at a Chemical Biology meeting last week, the suggestion seems to be that there are about 3000 viable drug targets encoded by those 23000 odd genes, not all of which are likley to be tractable small molecule targets
I never figured out where this number, 3000 came from. It certainly implies the good and thorough understanding of human physiology which I realy doubt. IMHO it is some rubbish guess from some rubbish Nature Reviews Something.
So 3000 is the estimate of the number of proteins which potentially can be targeted by small molecules based on current chemistry/screnning technologies.
Not the number of proteins related to desease phenotypes...
Thanks for the various tips shared on this blog. I have seen that many insurers offer shoppers generous savings if they choose to insure many cars together. A significant number of households currently have several vehicles these days, especially those with mature teenage young children still located at home, along with the savings on policies can easily soon increase. So it makes sense to look for a good deal.
Thanks for the tips you have discussed here. Another thing I would like to state is that laptop or computer memory needs generally rise along with other advances in the know-how. For instance, when new generations of cpus are brought to the market, there's usually a similar increase in the size and style demands of all laptop memory as well as hard drive room. This is because the program operated by way of these processor chips will inevitably increase in power to use the new technologies.
Excellent read, I just passed this onto a colleague who was doing some research on that. And he actually bought me lunch since I found it for him smile So let me rephrase that: Thank you for lunch! "Procrastination is the thief of time." by Edward Young.
1. Anon on December 11, 2009 4:56 PM writes...
Remember the smackdown on the diazaannulenes? http://pipeline.corante.com/archives/2007/11/29/neat_wish_it_were_true.php
Christl brings it again!
Permalink to Commenthttp://dx.doi.org/10.1002/anie.200901741
2. Jeffrey Soreff on December 12, 2009 9:47 PM writes...
I have a really dumb question. Has anyone tried looking for new drug leads by looking for binding at _all_ of the proteins coded for in the human genome, regardless of whether their function is known? With 23,000 genes, it seems like there should be the potential for a comparable number of useful drugs (ok, binding to structural proteins might not do anything useful...). Has anyone tried anything like that?
Permalink to Comment3. weirdo on December 12, 2009 10:19 PM writes...
You would need binding assays for all of them. To justify the expense of doing so, you'd need a reason or two. Even with reasons, academia and biotech and big pharma all put together have a pretty lousy track record of turning molecules that bind particular proteins selectively into actual drugs -- or even tools that give unambiguous answers.
But the short answer to your question is "yes". It's called "systems biology" and "phenotypic screening".
Permalink to Comment4. Jeffrey Soreff on December 12, 2009 10:50 PM writes...
Many thanks!
Permalink to Comment5. Mutatis Mutandis on December 13, 2009 7:34 AM writes...
I don't think it makes much sense to target "all" of them, but I've heard people discuss the idea of identifying the central proteins and interactions in the signalling networks through systems biology, and then systematically discovering molecules to target all of those.
They would of course be useful tool compounds to explore systems biology further. But you could also put them on the shelf with the confidence that sooner or later nearly all these critical interactions will be found to be relevant to a pathology of some kind.
It seems unlikely that people will try to do this through binding assays, I would bet more on phenotypical studies (HCS and microarrays) aiming to find drugs that mimic phenotypes established by RNAi. However, I'd like that to be done on primary cells or at least stem-cell derived cells.
Permalink to Comment6. petros on December 13, 2009 8:42 AM writes...
Having heard a couple of talks on the targets issue, at a Chemical Biology meeting last week, the suggestion seems to be that there are about 3000 viable drug targets encoded by those 23000 odd genes, not all of which are likley to be tractable small molecule targets
Permalink to Comment7. fromsgc on December 14, 2009 5:17 AM writes...
I never figured out where this number, 3000 came from. It certainly implies the good and thorough understanding of human physiology which I realy doubt. IMHO it is some rubbish guess from some rubbish Nature Reviews Something.
Permalink to Comment8. petros on December 14, 2009 6:10 AM writes...
The druggable genome was calculated by Hopkins & Groom in a collaboration between Pfizer and Inpharmatica
see http://www.oecd.org/dataoecd/35/0/35641354.pdf
But it was a Nature Rev Drug Discovery paper
Permalink to Comment9. fromsgc on December 14, 2009 6:38 AM writes...
Thanks for the link !
So 3000 is the estimate of the number of proteins which potentially can be targeted by small molecules based on current chemistry/screnning technologies.
Permalink to CommentNot the number of proteins related to desease phenotypes...
10. Grant Mayeda on March 1, 2012 3:30 PM writes...
Thanks for the various tips shared on this blog. I have seen that many insurers offer shoppers generous savings if they choose to insure many cars together. A significant number of households currently have several vehicles these days, especially those with mature teenage young children still located at home, along with the savings on policies can easily soon increase. So it makes sense to look for a good deal.
Permalink to Comment11. Karri Weissberg on May 16, 2012 3:30 PM writes...
Thanks for the tips you have discussed here. Another thing I would like to state is that laptop or computer memory needs generally rise along with other advances in the know-how. For instance, when new generations of cpus are brought to the market, there's usually a similar increase in the size and style demands of all laptop memory as well as hard drive room. This is because the program operated by way of these processor chips will inevitably increase in power to use the new technologies.
Permalink to Comment12. mulberry uk on July 9, 2012 6:04 AM writes...
Excellent read, I just passed this onto a colleague who was doing some research on that. And he actually bought me lunch since I found it for him smile So let me rephrase that: Thank you for lunch! "Procrastination is the thief of time." by Edward Young.
Permalink to Comment